{"id":390614,"date":"2018-08-06T00:00:00","date_gmt":"2018-08-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0015-2018-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-severe-us-eu-2018\/"},"modified":"2026-03-31T10:48:08","modified_gmt":"2026-03-31T10:48:08","slug":"unneim0015-2018-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-severe-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0015-2018-biopharma-chronic-obstructive-pulmonary-disease-unmet-need-severe-us-eu-2018\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Unmet Need | Severe | US\/EU | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p><abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>\u00a0is a progressive inflammatory respiratory tract and lung disease characterized by airflow obstruction and decreased lung function. The\u00a0<abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>\u00a0market continues to suffer from the absence of any therapies that can reverse disease progression and repair lung tissue. Smoking cessation is still the only option to slow or halt disease progression, and therapies that can reverse pathological processes and regenerate alveolar tissue have yet to be discovered. In the absence of a truly disease-modifying therapy, inhaled bronchodilator therapies are most commonly prescribed, and development has focused on improving breathing or reducing inflammation. Inhaled medications are primarily effective in reducing the burden of the disease by controlling symptoms, and various clinical trial end points, including\u00a0<abbr title=\"forced expiratory volume in 1 second\">FEV1<\/abbr>,\u00a0<abbr title=\"St. George's Respiratory Questionnaire\">SGRQ<\/abbr>, and\u00a0<abbr title=\"transition dyspnea index\">TDI<\/abbr>\u00a0focal score, are used to try to measure patients\u2019 improvement.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What clinical and nonclinical attributes are key influencers to pulmonologists\u2019 prescribing decisions, which have limited impact, and what are potential areas of hidden opportunities?<\/li>\n<li>How do market leaders Spiriva, Advair\/Seretide, and Symbicort perform on key treatment drivers and goals for\u00a0<abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>? How does their performance compare with one another, as well as that of\u00a0<abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr><abbr title=\"fixed-dose combination\">FDC<\/abbr>s such as Anoro and Stiolto\/Spiolto?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new\u00a0<abbr title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>\u00a0drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 60\u00a0U.S. and 30\u00a0European pulmonologists\u00a0fielded in May 2018<\/p>\n<p><strong>Key companies:<\/strong>\u00a0GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Sunovion<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Spiriva, Advair\/Seretide, Symbicort, Breo, Anoro, Stiolto\/Spiolto, Utibron\/Ultibro, Trelegy<\/p>\n","protected":false},"template":"","class_list":["post-390614","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390614\/revisions"}],"predecessor-version":[{"id":393738,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390614\/revisions\/393738"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}